Morningstar

Damien Conover, CFA

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

More From Damien Conover

New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover.
Damien Conover, CFA

Strong drug sales helped wide-moat J&J report a steady quarter, but increasing competitive threats to leading drugs and a relatively weak late-stage pipeline will be headwinds in the future.
Damien Conover, CFA

Despite an improving pipeline and slowing patent losses, a lackluster growth outlook will likely drive Pfizer to acquire assets in the near term.
Damien Conover, CFA

The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover.
Damien Conover, CFA

More About Damien Conover

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

Sponsor Center